The National Commission of Markets and Competition (CNMC) has decided to advance the acquisition of Esteve Teijin Healthcare by Oximesa to Phase 2—a more in-depth analysis in which parties considered affected can submit objections. According to the agency chaired by Cani Fernández, the transaction could lead to excessive dominance of the home respiratory therapy market.